COMM domain containing 3Genealiases: BUP · C10orf8
Q-omics provides the consensus-scored COMMD3 profile across patient tissues and cancer cell-line models. COMMD3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, COMMD3 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, COMMD3 RNA expression shows 19,519 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, KIRC, and ACC as cancer lineages where COMMD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COMMD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COMMD3 survival associations across molecular data types. COMMD3 RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COMMD3 RNA expression–survival associations across cancer types. High COMMD3 expression shows unfavorable associations in LIHC, SCLC, ACC and KICH, but favorable associations in SKCM and LUSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for COMMD3 RNA expression.
This table summarizes COMMD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COMMD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COMMD3 shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, BRCA, STAD and CHOL. The KIRC box plot shows higher COMMD3 RNA expression in tumor versus normal tissue (log2 FC = +0.672, t-test p < 0.001).
This table shows molecular features associated with COMMD3 in patient tissues and cancer cell lines. In patient samples, COMMD3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, COMMD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and SKIN.
